In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [


Journal

Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503

Informations de publication

Date de publication:
15 05 2019
Historique:
received: 13 08 2018
revised: 12 01 2019
accepted: 17 01 2019
pubmed: 22 1 2019
medline: 5 8 2020
entrez: 22 1 2019
Statut: ppublish

Résumé

Highly specific and sensitive biomarkers for pathologies related to dysfunctions in the basal ganglia circuit are of great value to assess therapeutic efficacy not only clinically to establish an early diagnosis, but also in terms of monitoring the efficacy of therapeutic interventions and decelerated neurodegeneration. The phosphodiesterase 10A (PDE10A) enzyme plays a central role in striatal signaling and is implicated in several neuropsychiatric disorders involving striatal pathology, such as Huntingtońs disease (HD) and schizophrenia. Inhibition of PDE10A activates the neurons in the striatum and consequently leads to alteration of behavioral aspects modulated by the striatal circuit. [

Identifiants

pubmed: 30664847
pii: S0006-8993(19)30038-1
doi: 10.1016/j.brainres.2019.01.021
pii:
doi:

Substances chimiques

2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione 0
Fluorine Radioisotopes 0
Phthalimides 0
Quinazolinones 0
Radiopharmaceuticals 0
PDE10A protein, human EC 3.1.4.-
Phosphoric Diester Hydrolases EC 3.1.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-145

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Marie M Svedberg (MM)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.

Katarina Varnäs (K)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden. Electronic address: katarina.varnas@ki.se.

Andrea Varrone (A)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden.

Nicholas Mitsios (N)

Science for Life Laboratory, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Jan Mulder (J)

Science for Life Laboratory, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Balázs Gulyás (B)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden; Translational Neuroscience Laboratory, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Vahri Beaumont (V)

CHDI Foundation/CHDI Management, Inc., Princeton, NY, USA.

Ignacio Munoz-Sanjuan (I)

CHDI Foundation/CHDI Management, Inc., Princeton, NY, USA.

Margaret M Zaleska (MM)

Pfizer Neuroscience, Cambridge, MA, USA.

Christopher J Schmidt (CJ)

Pfizer Neuroscience, Cambridge, MA, USA.

Christer Halldin (C)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76 Stockholm, Sweden; Translational Neuroscience Laboratory, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Ladislav Mrzljak (L)

CHDI Foundation/CHDI Management, Inc., Princeton, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH